Destiny Pharma and SporeGen® announce collaboration and Innovate UK grant award to co-develop novel, preventative treatment for COVID-19

Link to Full Article Destiny Pharma and SporeGen® announce collaboration and Innovate UK grant award to co-develop novel, preventative treatment for COVID-19 SPOR-COV™ prophylactic approach targets the innate immune system with potential to develop COVID-19 protection within a few days of treatment Innovate UK grant of £800,000 to support SPOR-COV™ programme over the next 18 months […]

Destiny Destiny Pharma welcomes NBIC #BiofilmAware campaign, launched today

Link to Full Article Destiny Pharma, as an NBIC industrial partner, is currently working on three NBIC funded research projects in collaboration with expert teams at the Universities of Cardiff, Sheffield and Southampton. The XF drug platform has demonstrated efficacy against bacteria in biofilms and we are looking forward to advancing these research assets towards […]

Destiny Pharma’s positive interim safety review of Phase 2b clinical trial of lead asset XF-73 in the prevention of post-surgical bacterial infections

Link to Full Article Destiny Pharma plc (“Destiny Pharma” or “the Company”) Positive interim safety review of Phase 2b clinical trial of lead asset XF-73 in the prevention of post-surgical bacterial infections Brighton, United Kingdom – 11 August 2020 – Destiny Pharma plc (AIM: DEST), a clinical stage biotechnology company focused on the development of novel […]

Destiny Pharma’s Update on Phase 2b clinical study of lead asset XF-73 in the prevention of post-surgical bacterial infections

Protocol amendment agreed with FDA to reduce Phase 2b study size without compromising its statistical power or clinical value Study two thirds enrolled. Recruitment now expected to complete by year end Planned study interim safety review to be announced in August 2020 Brighton, United Kingdom – 27 July 2020 – Destiny Pharma plc (AIM: DEST), […]

Pharma companies join forces to launch $1 billion fund to develop new antibiotics by 2030

Link to Full Article Twenty-three leading biopharmaceutical companies have joined forces to invest $1 billion in a fund to develop new antibiotics, which are needed urgently to fight the worldwide rise in antimicrobial-resistant superbugs. The AMR Action Fund, aims to bring 2-4 new antibiotics to patients by 2030. Through the AMR Action Fund, pharmaceutical companies will join […]

12 May 2020 – Posting of Annual Report and Notice of AGM

Destiny Pharma plc (“Destiny Pharma” or “the Company”) Posting of Annual Report and Accounts, and Notice of AGM Brighton, United Kingdom – 12 May 2020 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel, hospital infection prevention treatments that address the global challenge of antimicrobial resistance (AMR), announces that […]

Audited results for the year ended 31 December 2019 and clinical development update

Link to Full Article Company funded through to Q4 2021 Patient recruitment for XF-73 Phase 2b trial temporarily paused due to COVID-19 pandemic Brighton, United Kingdom – 29 April 2020 – Destiny Pharma (“the Company”; AIM: DEST), a clinical stage biotechnology company focused on the development of novel, hospital infection prevention treatments that address the global […]

Clinical and Business Update

Link to Full Article Phase 2b study on track to complete recruitment in mid-2020 Earlier grant funded programs progressing to plan Company well-funded through to mid-2021 Brighton, United Kingdom – 3 March 2020 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel, hospital infection prevention treatments that address […]

Update on the development of XF drug formulations

Link to Full Article Destiny Pharma plc (“Destiny Pharma” or “the Company”) Positive update on the development of new XF‑platform drug formulations Collaboration with MedPharm Ltd. delivers data profiling new XF‑platform drug formulations as potential treatments for dermal and ocular infections New formulations support a growing pipeline alongside lead drug asset, XF-73, currently in Phase […]

Destiny Pharma appoints Dr Debra Barker as Non-Executive Director

Link to Full Article Experienced pharmaceutical executive and medical director with expertise in anti-infective drug development and in-licensing Brighton, United Kingdom – 2 December 2019 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel antimicrobial drugs that address clear commercial opportunities and also address the global problem of […]